Five advantages of the AstraZeneca-Oxford vaccine

Five advantages of the AstraZeneca-Oxford vaccine

Britain starts today (Monday) using the British laboratory vaccine AstraZeneca and Oxford University “AstraZeneca-Oxford”, making it the first country in the world to use this vaccine.

In what comes 5 things to know about this vaccine, which was approved by the medicines Regulatory Authority in India Sunday, after both the United Kingdom and Argentina Wednesday.

1. Cheap
One of the most notable features of the AstraZeneca and Oxford University vaccine is that it cost about €2.50 per dose (about $3), compared to about $20 for the Pfizer-Biontech vaccine, and about $30 for the dose of the Muderna vaccine, news sites reported.

2. Easy to store
The AstraZeneca-Oxford vaccine requires a temperature of between 2 and 8°C, which is the normal refrigerator temperature, unlike the long-term vaccines of our moder and fizer-Biontech, which can be stored only at very low temperatures, up to 20°C for the first vaccine, and 70°C for the second vaccine.

3. Effective vaccine
The general manager of AstraZeneca laboratories declared that the vaccine is capable of fighting the new strain of Corona virus, which caused a new infection in Britain.

Pascal Sorio told Sunday Times newspaper “We see at the present time that the vaccine is supposed to be effective” against the new breed, “but this can not be verified, and we will carry out tests”.

He confirmed that new formulas were prepared for fear of any possibility, expressing his hope that they should not be used, but he added “We should be ready”.

4- Rare side effects
It is the first vaccine approved by the Lancet medical reference magazine on December 8, declaring in data published that the AstraZeneca vaccine is safe.

The side effects of the vaccine are very rare at the current stage.

Of the 23,000 and 754 volunteers involved in the tests, one person who received the vaccine recorded a “serious impact that may be linked” to the vaccine, according to the magazine’s data.

That person was hit by a rare spinal cord inflammation, leading to an early September suspension of trials.

5. Viral carrier
AstraZeneca’s vaccine is based on a “viral carrier”, meaning that it is based on another virus, a virus that spreads among monkeys, that has been modified and adapted to fight the new Corona virus.
British authorities have ordered 100 million doses of the AstraZeneca-Oxford vaccine, of which 520,000 will be available on Monday, the Health Ministry said.

Minister of Health Matt Hankok said “I am happy to launch the Oxford vaccine that came as a result of the British flag. This represents a shift in our fight against this terrible virus, and I hope it will restore hope to all people that the end of the pandemic is in our view.”

Argentina also licensed the vaccine AstraZeneca-Oxford, as India licensed it Sunday, which will allow this 1.3 billion-strong country to launch one of the world’s largest vaccination campaigns.

However, the license for AstraZeneca vaccine in Europe will not take place in January, according to the European medicines Agency, while the United States does not intend to approve it before April.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here